Pharmacogenomics of Lithium Response in Bipolar Disorder.

Genome-Wide Association Study (GWAS) bipolar disorder lithium personalized medicine pharmacogenomics predictive models

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
24 Mar 2021
Historique:
received: 02 03 2021
revised: 19 03 2021
accepted: 21 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Despite being the most widely studied mood stabilizer, researchers have not confirmed a mechanism for lithium's therapeutic efficacy in Bipolar Disorder (BD). Pharmacogenomic applications may be clinically useful in the future for identifying lithium-responsive patients and facilitating personalized treatment. Six genome-wide association studies (GWAS) reviewed here present evidence of genetic variations related to lithium responsivity and side effect expression. Variants were found on genes regulating the glutamate system, including GAD-like gene 1 (

Identifiants

pubmed: 33804842
pii: ph14040287
doi: 10.3390/ph14040287
pmc: PMC8063790
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH121580
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR003168
Pays : United States

Références

Biol Psychiatry. 2010 Feb 1;67(3):279-82
pubmed: 19875103
JAMA Psychiatry. 2018 Jan 1;75(1):65-74
pubmed: 29121268
Int J Bipolar Disord. 2020 Dec 16;8(1):40
pubmed: 33330966
Mol Psychiatry. 2020 Mar 16;:
pubmed: 32203155
Arch Gen Psychiatry. 2012 Sep;69(9):904-12
pubmed: 22566560
Mol Psychiatry. 2009 Jul;14(7):696-704, 647
pubmed: 18347601
Psychiatry Clin Neurosci. 2003 Jun;57(3):243-50
pubmed: 12753562
Expert Rev Mol Med. 2004 Oct 18;6(21):1-18
pubmed: 15488156
Int Clin Psychopharmacol. 2019 Jul;34(4):189-205
pubmed: 30932919
Aust N Z J Psychiatry. 2012 Mar;46(3):192-211
pubmed: 22391277
Psychiatr Genet. 2015 Feb;25(1):39-40
pubmed: 25415457
Mol Psychiatry. 2015 Jun;20(6):661-70
pubmed: 25687772
Sci Rep. 2021 Jan 13;11(1):1155
pubmed: 33441847
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
ACS Chem Neurosci. 2014 Jun 18;5(6):413-21
pubmed: 24625017
Ther Adv Chronic Dis. 2011 May;2(3):209-26
pubmed: 23251751
Mol Psychiatry. 2017 Aug;22(8):1223
pubmed: 28194006
Int J Neuropsychopharmacol. 2003 Dec;6(4):421-4
pubmed: 14604458
Transl Psychiatry. 2018 Sep 5;8(1):183
pubmed: 30185780
J Affect Disord. 2015 Jun 1;178:224-8
pubmed: 25827507
PLoS One. 2018 Mar 20;13(3):e0194044
pubmed: 29558500
Neuroscience. 2008 Feb 19;151(4):1184-97
pubmed: 18222042
Autoimmune Dis. 2013;2013:761046
pubmed: 23509613
Pharmacogenomics. 2010 Oct;11(10):1439-65
pubmed: 21047205
Bipolar Disord. 2014 Mar;16(2):151-8
pubmed: 24636202
J Psychiatr Res. 2012 Dec;46(12):1564-8
pubmed: 23000368
CNS Spectr. 2013 Oct;18(5):242-51
pubmed: 23472710
CNS Spectr. 2010 Feb;15(2):95-109
pubmed: 20414155
Bipolar Disord. 2009 Jun;11 Suppl 2:92-109
pubmed: 19538689
Bipolar Disord. 2001 Apr;3(2):63-7
pubmed: 11333064
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2642-7
pubmed: 9482940
Mol Psychiatry. 2016 Sep;21(9):1290-7
pubmed: 26503763
Br J Psychiatry. 2007 Dec;191:474-6
pubmed: 18055949
BMC Psychiatry. 2016 May 05;16:129
pubmed: 27150464
J Biol Chem. 2013 Jul 12;288(28):20111-20
pubmed: 23696638
Cochrane Database Syst Rev. 2015 Oct 28;(10):CD003834
pubmed: 26509923
Genes Brain Behav. 2011 Nov;10(8):852-61
pubmed: 21781277
J Affect Disord. 1993 Sep;29(1):49-52
pubmed: 8254143
PLoS One. 2013 Jun 19;8(6):e65636
pubmed: 23840348
Acta Psychiatr Scand. 2020 Jun;141(6):522-533
pubmed: 32068882
J Clin Psychiatry. 2002 Oct;63(10):942-7
pubmed: 12416605
J Affect Disord. 2018 Mar 15;229:410-414
pubmed: 29331701
J Affect Disord. 1994 Oct;32(2):85-95
pubmed: 7829768
Nat Genet. 2019 May;51(5):793-803
pubmed: 31043756
Int Clin Psychopharmacol. 2011 Nov;26(6):323-8
pubmed: 21876441
J Biol Chem. 2010 Apr 16;285(16):12426-34
pubmed: 20164195
J Clin Psychopharmacol. 1999 Oct;19(5):427-34
pubmed: 10505584
Am J Psychiatry. 2009 Jun;166(6):718-25
pubmed: 19448189
Pharmacogenomics. 2015;16(14):1547-63
pubmed: 26343379
World J Biol Psychiatry. 2018 Dec;19(8):619-632
pubmed: 28095742
Cereb Cortex. 2019 Feb 1;29(2):505-516
pubmed: 29293918
N Engl J Med. 2014 Jan 9;370(2):119-28
pubmed: 24369049
J Affect Disord. 2007 Dec;104(1-3):185-90
pubmed: 17442400
Biol Psychiatry. 1999 Feb 15;45(4):453-7
pubmed: 10071717
Brain Res Rev. 2009 Apr;60(1):43-56
pubmed: 19146876
Sci Rep. 2020 Jul 22;10(1):12239
pubmed: 32699220
Psychiatry Res. 2017 May;251:217-220
pubmed: 28214779
J Neurosci. 2008 Jan 2;28(1):68-79
pubmed: 18171924
Pharmacogenomics. 2008 Nov;9(11):1595-603
pubmed: 19018715
Am J Psychiatry. 2015 Jan;172(1):94-5
pubmed: 25553497
J Affect Disord. 2015 Jan 1;170:95-103
pubmed: 25237732
Psychiatry Res. 2019 Aug;278:42-50
pubmed: 31146140
Biol Psychiatry. 2009 May 1;65(9):792-800
pubmed: 19058788
Lancet. 2016 Mar 12;387(10023):1085-1093
pubmed: 26806518
Bipolar Disord. 2018 Sep;20(6):506-514
pubmed: 29527766

Auteurs

Courtney M Vecera (CM)

Experimental Therapeutics and Molecular Pathophysiology Program, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Center of Excellence on Mood Disorders, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.

Gabriel R Fries (GR)

Center of Excellence on Mood Disorders, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Center for Precision Health, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77054, USA.

Lokesh R Shahani (LR)

Center of Excellence on Mood Disorders, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.

Jair C Soares (JC)

Experimental Therapeutics and Molecular Pathophysiology Program, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Center of Excellence on Mood Disorders, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.

Rodrigo Machado-Vieira (R)

Experimental Therapeutics and Molecular Pathophysiology Program, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Center of Excellence on Mood Disorders, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77054, USA.

Classifications MeSH